Intergy Private Wealth LLC Increases Stock Position in Novartis AG (NYSE:NVS)

Intergy Private Wealth LLC raised its stake in Novartis AG (NYSE:NVS) by 3.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,757 shares of the company’s stock after acquiring an additional 104 shares during the period. Intergy Private Wealth LLC’s holdings in Novartis were worth $307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of NVS. Continuum Advisory LLC grew its position in shares of Novartis by 10.3% during the fourth quarter. Continuum Advisory LLC now owns 1,021 shares of the company’s stock worth $99,000 after acquiring an additional 95 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its stake in Novartis by 0.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company’s stock worth $1,254,000 after purchasing an additional 100 shares during the period. Rothschild Investment LLC grew its position in Novartis by 0.6% during the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company’s stock worth $1,623,000 after purchasing an additional 101 shares during the last quarter. Meridian Wealth Management LLC increased its stake in Novartis by 2.6% in the fourth quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company’s stock valued at $405,000 after purchasing an additional 106 shares during the period. Finally, Angeles Wealth Management LLC increased its stake in Novartis by 3.5% in the fourth quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company’s stock valued at $316,000 after purchasing an additional 110 shares during the period. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Trading Up 0.2%

Shares of Novartis stock opened at $118.02 on Friday. The firm has a market cap of $249.31 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.60. Novartis AG has a 52-week low of $96.06 and a 52-week high of $120.92. The company’s 50-day simple moving average is $110.62 and its 200-day simple moving average is $106.56. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, April 29th. The company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $2.12 by $0.16. The company had revenue of $13.23 billion for the quarter, compared to analyst estimates of $12.92 billion. Novartis had a return on equity of 37.24% and a net margin of 23.56%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.80 EPS. As a group, equities research analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.

Analysts Set New Price Targets

NVS has been the subject of several recent research reports. Morgan Stanley began coverage on shares of Novartis in a research note on Wednesday, February 12th. They set an “underweight” rating for the company. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Wall Street Zen upgraded Novartis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 8th. Finally, BNP Paribas raised Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Novartis has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.